Companies seek approval for meningococcal serogroup B vaccines
Novartis and Pfizer today announced that they have submitted applications to the US Food and Drug Administration (FDA) for marketing approval of their vaccines against Neisseria meningitidis serogroup B infection.
The FDA had granted each company breakthrough therapy designations for their vaccines, Pfizer in March and Novartis in April. Both companies are seeking indications for use in those aged 10 to 25.
Currently, there is no vaccine in the United States approved for use against serogroup B, which accounted for about 40% of N meningitidis infections in the country in 2012. Though antibiotics can be used to treat infections, the disease is fatal for about 10% to 15% of patients, and 11% to 19% of survivors have complications that cause long-term disability, according to the statement from Pfizer.
Outbreaks involving serogroup B occurred on some college campuses in 2013, and nearly 30,000 doses of the Novartis vaccine (Bexsero) were provided to students and staff at Princeton University and the University of California at Santa Barbara under an FDA investigational new drug designation in response to the events, according to the Novartis statement.
The company said the US Centers for Disease Control and Prevention (CDC) has recommended that incoming freshmen at Princeton receive Bexsero, which is already approved in the European Union, Australia, and Canada.
Jun 17 Novartis press release
Jun 17 Pfizer press release
USDA licenses first vaccine for porcine epidemic diarrhea virus
The US Department of Agriculture has issued a conditional license for the country's first licensed vaccine for controlling porcine epidemic diarrhea virus (PEDv) in swine, the agency's Animal and Plant Health Inspection Service (APHIS) said in a news release yesterday.
The vaccine, made by Harrisvaccines, Inc., of Ames, Iowa, will be used to vaccinate sows so they transmit antibodies through their milk to protect newborn piglets, the APHIS said in the release. PEDv has decimated US swine populations and has been up to 100% fatal in piglets, Bloomberg News reported.
"Preliminary studies have been promising, and they've shown sufficient data that we think the vaccine will be effective," the APHIS said. "The company will continue working toward completing the requirements for a full license. In the meantime, there are no restrictions on vaccine use under the conditional license."
Harrisvaccines has sold nearly 2 million doses of its PEDv vaccine through veterinary prescriptions, the company said in a release.
Jun 16 APHIS news release
Jun 16 Bloomberg story
Jun 16 Harrisvaccines news release